Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
almitrine + dihydroergocristine
- Development stage
- Preclinical
- Lead developer
- Servier
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination drug consisting of almitrine and dihydroergocristine. Almitrine is a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. Dihydroergocristine is an ergot alkaloid with partial agonist activity on dopaminergic and alpha-adrenergic receptors and antagonist activity on serotonin receptors. This combination has been used for treating age-related cerebral disorders and cerebrovascular conditions.
02
Targets
ADRA1A (α1A)DRD2 (Dopamine D2 Receptor)5-HT2 (5-HT2 receptor family)ADRA1 (Alpha-1 adrenergic receptor family)5-HT (Serotonin receptors)
Beyond the preview
Go deeper on almitrine + dihydroergocristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on almitrine + dihydroergocristine.